VcMMAE (Synonyms: MC-VC-PAB-MMAE, Vedotin) |
Catalog No.GC37891
One-Click Copy Product Info
|
VcMMAE is a drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs), consisting of the microtubule inhibitor monomethyl auristatin E (MMAE) and a cleavable valine-citrulline (vc) linker.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 646502-53-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
VcMMAE is a drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs), consisting of the microtubule inhibitor monomethyl auristatin E (MMAE) and a cleavable valine-citrulline (vc) linker[1-2]. In the ADC structure, VcMMAE is covalently linked to the antibody via the maleimide group of its linker. Upon specific cleavage by cancer cell lysosomes, VcMMAE releases the cytotoxic MMAE, thereby inhibiting tubulin polymerization and inducing tumor cell apoptosis[3-4].
In vitro, when conjugated with the anti-HER2 antibody H32 (0.02–0.78nM) and applied to HER2-positive cancer cells such as N87, SK-BR-3, and BT474 for 16 hours, VcMMAE significantly inhibited cancer cell viability and induced apoptosis[5]. The conjugate of VcMMAE with Rituximab (100–1000ng/mL) treatment of CD20-positive Raji cells for 48–72 hours markedly reduced cell viability and induced cell death[6].
In vivo, the conjugate of VcMMAE with the chimeric monoclonal antibody cAC10 targeting CD30 (1-30mg/kg), administered via tail vein injection every 4 days to tumor-bearing SCID mice, significantly suppressed the growth of CD30-positive anaplastic large cell lymphoma (Karpas 299) and Hodgkin's disease (L540cy) xenografts, leading to complete tumor regression[7]. The conjugate of VcMMAE with the anti-CD22 monoclonal antibody HB22.7 (7.5mg/kg), administered as a single intraperitoneal injection to tumor-bearing ICR-SCID mice, significantly inhibited the growth of DoHH2 (transformed follicular lymphoma) and Granta 519 (mantle cell lymphoma) xenografts and induced complete tumor regression[8].
References:
[1] Best RL, LaPointe NE, Azarenko O, et al. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy. Toxicol Appl Pharmacol. 2021 Jun 15;421:115534.
[2] Pollack VA, Alvarez E, Tse KF, et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol. 2007 Aug;60(3):423-35.
[3] Vaklavas C, Forero A. Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE). BioDrugs. 2014 Jun;28(3):253-63.
[4] Zhang J, Li M, Li W, et al. Mechanistic Insights into Anti-Nectin4-VcMMAE-Induced Ocular Toxicity: From Cellular Uptake Pathways to Molecular Modification. Int J Mol Sci. 2025 May 22;26(11):4996.
[5] Chiang ZC, Chiu YK, Lee CC, et al. Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells. PLoS One. 2020 Sep 28;15(9):e0239813.
[6] Abdollahpour-Alitappeh M, Hashemi Karouei SM, Lotfinia M, et al. Amanzadeh A, Habibi-Anbouhi M. A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line. Artif Cells Nanomed Biotechnol. 2018;46(sup2):1-8.
[7] Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65.
[8] Abuhay M, Kato J, Tuscano E, et al. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity. Cancer Immunol Immunother. 2016 Oct;65(10):1169-75.
| Cell experiment [1]: | |
Cell lines | N87 (gastric carcinoma), SK-BR-3 and BT474 (breast adenocarcinoma) HER2-positive cancer cell lines. |
Preparation Method | Cells were cultured in RPMI-1640 or hybrid-Care medium supplemented with 10% fetal bovine serum at 37°C, 5% CO₂. Cells were treated with H32-VcMMAE at concentrations ranging from 0.02 to 0.78nM for 16 hours, followed by replacement with fresh medium and further incubation for 3 days. |
Reaction Conditions | 0.02 to 0.78μM; 16 hours |
Applications | H32-VcMMAE exhibited potent cytotoxicity against HER2-positive cells, with IC₅₀ values of 0.50nM (N87), 0.03nM (SK-BR-3), and 0.02nM (BT474). The ADC induced targeted cell death via microtubule disruption after internalization and lysosomal cleavage of the VC linker, releasing MMAE. |
| Animal experiment [2]: | |
Animal models | ICR-SCID mice bearing DoHH2 (transformed follicular lymphoma) and Granta 519 (mantle cell lymphoma) xenografts. |
Preparation Method | Mice were irradiated (400 rads, whole body) and inoculated subcutaneously with 10⁷ tumor cells. When tumors reached 100–200mm³, a single dose of HB22.7-VcMMAE (7.5mg/kg) was administered intraperitoneally. Tumor volume and toxicity indicators were monitored for 15–20 days. |
Dosage form | 7.5mg/kg; i.p.; Single injection. |
Applications | HB22.7-VcMMAE induced complete and durable tumor regression in 100% of DoHH2 xenografts and 90% of Granta 519 xenografts. |
References: | |
| Cas No. | 646502-53-6 | SDF | |
| Synonyms | MC-VC-PAB-MMAE, Vedotin | ||
| Canonical SMILES | CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(NC1=CC=C(COC(N(C)[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N2[C@@]([C@H](OC)[C@@H](C)C(N[C@H](C)[C@@H](O)C3=CC=CC=C3)=O)([H])CCC2)=O)C)=O)=O)=O)C=C1)=O)=O)NC(CCCCCN4C(C=CC4=O)=O)=O | ||
| Formula | C68H105N11O15 | M.Wt | 1316.63 |
| Solubility | DMSO: ≥ 54 mg/mL (41.01 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 759.5 μL | 3.7976 mL | 7.5951 mL |
| 5 mM | 151.9 μL | 759.5 μL | 1.519 mL |
| 10 mM | 76 μL | 379.8 μL | 759.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)